Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-small- Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06496659
What this trial is testing

Segmentectomy After Induction Therapy (SAINT)

Who this might be right for
Segmentectomy
Northwestern University 25
Testing effectiveness (Phase 2)Study completedNCT01836679
What this trial is testing

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Chipscreen Biosciences, Ltd. 124
Testing effectiveness (Phase 2)Study completedNCT00750269
What this trial is testing

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Radiation Therapy Oncology Group 120
Not applicableLooking for participantsNCT06730503
What this trial is testing

Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 250
Not applicableLooking for participantsNCT05754203
What this trial is testing

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Who this might be right for
Lung CancerImmune Checkpoint InhibitorRadiotherapy
Xinqiao Hospital of Chongqing 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07247786
What this trial is testing

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

Who this might be right for
Non Small Cell Lung CancerRespiratory Tract Neoplasm
Fundación GECP 68
Large-scale testing (Phase 3)Looking for participantsNCT06031246
What this trial is testing

Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

Who this might be right for
Lung AdenocarcinomaLymph Node Metastasis
Fudan University 634
Early research (Phase 1)WithdrawnNCT06681870
What this trial is testing

ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Who this might be right for
CLDN6-positive Solid TumorOvarian CancerEndometrial Cancer+3 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Ended earlyNCT01515969
What this trial is testing

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC), RecurrentNon-small Cell Lung Cancer (NSCLC), Stage IV
Heather Wakelee 9
Not applicableUnknownNCT02988141
What this trial is testing

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
Jianxing He 100
Early research (Phase 1)Study completedNCT00432562
What this trial is testing

A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.

Who this might be right for
Breast CancerNon-small Cell Lung CancerNon-Hodgkins Lymphoma
Mast Therapeutics, Inc. 31
Large-scale testing (Phase 3)UnknownNCT03991403
What this trial is testing

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Samsung Medical Center 228
Not applicableActive Not RecruitingNCT07215962
What this trial is testing

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb 300
Early research (Phase 1)Ended earlyNCT00265603
What this trial is testing

Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Atlantic Health System 16
Testing effectiveness (Phase 2)Study completedNCT00881296
What this trial is testing

Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hamamatsu University 60
Testing effectiveness (Phase 2)Study completedNCT04249362
What this trial is testing

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 102
Early research (Phase 1)Study completedNCT01336842
What this trial is testing

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Who this might be right for
Solid TumorsNon-Small Cell Lung Cancer (NSCLC)
University of California, Davis 23
Testing effectiveness (Phase 2)Study completedNCT00004979
What this trial is testing

Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03970746
What this trial is testing

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Who this might be right for
Non Small Cell Lung Cancer
PDC*line Pharma SAS 73
Large-scale testing (Phase 3)Study completedNCT01850303
What this trial is testing

Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer (Squamous or Non Squamous)
Intergroupe Francophone de Cancerologie Thoracique 632
Next Page